Evidence lacking on benefits of cannabis for mental health, evidence of harms stronger

Publicly released:
International
Photo by Wesley Gibbs on Unsplash
Photo by Wesley Gibbs on Unsplash

There remains a lack of evidence on whether cannabis can help people with mental health conditions, according to a review by international scientists who say future research must fill these gaps as cannabis use becomes more widespread and socially acceptable. The team looked at the available evidence to assess the use of cannabis for a variety of mental health conditions such as PTSD, anxiety, depression, bipolar disorder, ADHD, psychosis, and more. They say that, along with the lack of evidence of effectiveness to treat these conditions, using cannabis also comes with known risks, including worsening mania symptoms and ability to cope with life among bipolar patients, and an increase in psychotic symptoms among patients with psychotic disorders. They also report that around a third of people who use cannabis develop a cannabis use disorder, when use starts to interfere with everyday life. There is not currently enough evidence to support the use of cannabis for the treatment of mental health conditions, and use should be discouraged among young people and those with conditions such as biploar or psychosis, the authors conclude.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo lifts.
Journal/
conference:
JAMA Internal Medicine
Research:Paper
Organisation/s: Center to Improve Veteran Involvement in Care (CIVIC), USA
Funder: Drs Kansagara and Ayers are supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health (NOMAD PROJ-03570). Dr Terry is supported by grant IK4BX006799 from the US Department of Veterans Affairs, Biomedical Laboratory Research and Development Service. Dr D’Souza is supported by the US Department of Veterans Affairs (grant 5I01CX002378), National Institute on Drug Abuse (grants 1R01DA058862, 5R01DA054314, 5R21DA058138, 1R03DA054453, 1R21DA052864, 1R01DA052846, and 5R21DA054491). Conflict of Interest Disclosures: Dr Kansagara reported grants from the Veterans Health Administration during the conduct of the study. Dr Terry reported grants from the US Department of Veterans Affairs and research funding from Jazz Pharmaceuticals outside the submitted work; and is an employee of the US Department of Veterans Affairs. Dr D’Souza reported grants from the National Institutes of Health outside the submitted work. No other disclosures were reported.
Media Contact/s
Contact details are only visible to registered journalists.